A Phase 1, First-in-Human Study of CT-95, a Mesothelin-Directed Bispecific T Cell Engager (TCE) in Subjects with Advanced Solid Tumors
Previous
Previous
Targeting Solid Tumors with pH-Dependent TCE: First in Human Development of CT-202
Next
Next